retatrutide clinical trial parkinson Triple hormone receptor agonist for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a Retatrutide Results: 28.3% Weight Loss

The most used medications were semaglutide (54%), liraglutide (39%), and tirzepatide (7%)

The injectable drug, initially only used as diabetes medication, is the first drug since Saxenda (2014) approved to treat chronic weight management in the 70% of American adults who are obese or overweight.

Allulose for the attenuation of postprandial blood glucose levels in healthy humans: A systematic review and meta-analysis

The bundle focuses on high-protein meals, balanced food choices, hydration, gentle nutrition, and easy wellness routines to help make everyday life feel more manageable

Unlike traditional GLP-1 agonists, this investigational drug activates three receptors simultaneouslyGLP-1, GIP, and glucagon.

Both are common among patients with diabetes and obesity, yet until recently, treatment options were mostly limited to lifestyle interventions or devices like continuous positive airway pressure (CPAP) machines